Oxford BioTherapeutics
- Revenue£2.1 MFY, 2018
- Total Funding$21.6 M
OverviewSuggest Edit
Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.
| Type | Private | |
| Founded | 2004 | |
| HQ | Milton, GB | Map |
| Website | oxfordbiotherapeutics.com |
Recent NewsAll News
- Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target
- Global Antibody Drug Conjugates Market Research 2021 Featuring Major Players - Bayer, Concortis Biotherapeutics, F. Hoffman-La Roche, Immunomedics, and Oxford BioTherapeutics
- Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076
- Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
Key People/Management at Oxford BioTherapeutics
Jean-Pierre Bizzari
Fiona Irvine
John McHutchison
Abderrahim Fandi
Ken Sayre
Jason Gould
Oxford BioTherapeutics Office Locations
Oxford BioTherapeutics Financials and Metrics
Summary Metrics
Founding Date | 2004 |
Oxford BioTherapeutics total Funding | $21.6 m |
Oxford BioTherapeutics latest funding size | $10 m |
Time since last funding | 7 years ago |
Oxford BioTherapeutics investors | Silicon Valley Bank, Oxford Capital Partners, Catapult Venture Managers, South East Growth Fund & Management |
Oxford BioTherapeutics Revenue
| GBP | |
|---|---|
Revenue (FY, 2018) | 2.1m |
Net income (FY, 2018) | (6.5m) |
EBIT (FY, 2018) | (6.5m) |
Cash (31-Dec-2018) | 3.6m |
| GBP | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|
Revenue | 427.3k | 293.8k | 429.5k | 2.0m | 3.0m | 4.5m | 2.1m | |
Cost of goods sold | 82.0k | 125.3k | 117.2k | 157.4k | 480.4k | 438.6k | ||
Gross profit | 345.3k | 176.7k | 272.1k | 1.5m | 2.6m | |||
Gross profit Margin, % | 81% | 60% | 63% | 76% | 85% |
| GBP | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 79.3k | 110.4k | 37.8k | 550.7k | 3.7k | 577.2k | 9.2m | 4.0m | 2.1m | 1.2m | 2.6m | 821.4k | 3.1m | 4.3m | 3.6m |
Accounts Receivable | 135.3k | 15.2k | 33.4k | 727.2k | 958.6k | 1.2m | 2.6m | 2.9m | 168.5k | 25.5k | 3.6k | ||||
Inventories | 19.3k | 8.1k | 8.8k | 14.1k | 18.6k | 17.2k | 9.7k | 9.8k | 9.8k | ||||||
Current Assets | 174.7k | 250.4k | 178.3k | 829.7k | 364.3k | 971.6k | 9.9m | 5.0m | 3.4m | 3.8m | 5.5m | 2.4m | 4.4m | 5.7m | 5.1m |
| GBP | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|
Net Income | (546.5k) | (1.3m) | (1.2m) | (1.6m) | (5.6m) | (6.0m) | (2.3m) |
Income Taxes Paid | 1.2m | 964.4k |
| GBP | FY, 2004 |
|---|---|
Financial Leverage | 7.6 x |
Oxford BioTherapeutics Cybersecurity Score
Oxford BioTherapeutics Online and Social Media Presence
Oxford BioTherapeutics's Trends
Oxford BioTherapeutics News and Updates
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target
Global Antibody Drug Conjugates Market Research 2021 Featuring Major Players - Bayer, Concortis Biotherapeutics, F. Hoffman-La Roche, Immunomedics, and Oxford BioTherapeutics
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
Oxford BioTherapeutics Frequently Asked Questions
When was Oxford BioTherapeutics founded?
Oxford BioTherapeutics was founded in 2004.
Who are Oxford BioTherapeutics key executives?
Oxford BioTherapeutics's key executives are Jean-Pierre Bizzari, Fiona Irvine and John McHutchison.
How many employees does Oxford BioTherapeutics have?
Oxford BioTherapeutics has 31 employees.
What is Oxford BioTherapeutics revenue?
Latest Oxford BioTherapeutics annual revenue is £2.1 m.
What is Oxford BioTherapeutics revenue per employee?
Latest Oxford BioTherapeutics revenue per employee is £67.4 k.
Who are Oxford BioTherapeutics competitors?
Competitors of Oxford BioTherapeutics include Ajinomoto Bio-Pharma Services, Adverum Biotechnologies and UniQure.
Where is Oxford BioTherapeutics headquarters?
Oxford BioTherapeutics headquarters is located at 94a Innovation Dr, Milton.
Where are Oxford BioTherapeutics offices?
Oxford BioTherapeutics has offices in Milton and San Jose.
How many offices does Oxford BioTherapeutics have?
Oxford BioTherapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies